PARSIPPANY, N.J., July 18, 2024 /PRNewswire/ -- Pierre Fabre Pharmaceuticals Inc. announces the acceptance by U.S Food and Drug Administration (FDA) of the Biologics License Application (BLA) and Priority Review of Tabelecleucel (Tab-cel®), indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. There are no FDA approved therapies in this treatment setting.
Pierre Fabre overactive bladder med wins approval
CASTRES, France, June 28, 2024 /PRNewswire/ -- The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients* in Europe. In 2022, Pierre Fabre Laboratories acquired the exclusive license for vibegron from Urovant Sciences Gmbh for the registration and commercialization of this innovative treatment in the European Economic Area. The decision of the EC will be applicable to all EU member states as well as Iceland, Liechtenstein, and Norway. OBGEMSA™ is a trademark owned by Urovant Sciences.
Pierre Fabre`s Obgemsa (vibegron) Receives Approval In Europe
May 16, 2024 – Pierre Fabre Laboratories has been awarded the highest level of the Digital Responsibility label for its commitment to a more environmentally and socially responsible digital industry. Overseen by Lucie, an agency specializing in CSR label management, the Digital Responsibility label (Label Numérique Responsable) is based on a set of guidelines developed by the Institute for Sustainable IT (INR) (Institut
CASTRES, France, April 26, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSA™ (vibegron under the international non-proprietary name) for the symptomatic treatment of adult patients with overactive bladder syndrome (OAB). Pierre Fabre Laboratories acquired an exclusive license from Urovant Sciences to register and commercialize vibegron in the European Economic Area in 2022. OBGEMSA™ is a trademark owned by Urovant Sciences GmbH.
Pierre Fabre Laboratories has appointed Adriana Herrera to the position of Chief Executive Officer of Pierre Fabre Pharmaceuticals Inc., its new Medical Care affiliate in the U.S.
Castres, France – March 28, 2024. Pierre Fabre Laboratories has unveiled the first global study on the epidemiology of rosacea, published in February 2024 in the prestigious Journal of the American Academy of Dermatology1 (JAAD). Conducted as part of the ALL2 project, this study provides an unprecedented perspective on the prevalence of rosacea globally, highlighting significant variations by age, gender, geographic region and impacts on quality of life and stigmatizatio